特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
731757

1型糖尿病:市場競争環境 (2026年まで)

Type 1 Diabetes: Competitive Landscape to 2026

出版日: | 発行: GlobalData | ページ情報: 英文 48 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
1型糖尿病:市場競争環境 (2026年まで)
出版日: 2018年09月30日
発行: GlobalData
ページ情報: 英文 48 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、1型糖尿病 (T1D) の治療薬の治験・上市の見通しについて分析し、治験の全体的な進展状況 (地域別の内訳、初期/後期段階にある製品、主なスポンサーなど) や、主要なパイプライン製品の治験動向 (治験段階別)、今後の市場規模の予測値、現在/将来の代表的企業の概略、今後の市場動向の見通しなどを調査しております。

第1章 序論

第2章 エグゼクティブ・サマリー

第3章 イントロダクション

  • 分析範囲
  • 疾患の概要と疫学

第4章 パイプライン製品の評価

  • パイプライン製品の概要
  • パイプライン製品:国/地域別の内訳
  • パイプライン製品:分子の種類別/標的別の内訳
  • 指定薬の治験動向
  • 治験中の製品

第5章 治験の評価

  • 治験の概要
  • 治験:1型糖尿病の治験の大手スポンサー
  • 治験:地域別の内訳
  • 治療領域別の進行状況の見通し
  • 参加率の分析

第6章 商業面での評価

  • 主な上市済み製品
  • 現在/将来の企業

第7章 競争環境の分析 (通算11年間分)

  • イベントの分類:概要
  • 米国
  • 欧州主要5ヶ国 (5EU)
  • 日本・中国

第8章 付録

目次
Product Code: GDHC015CL

Type 1 Diabetes (T1D) is an autoimmune disease that permanently destroys beta cells of the pancreatic islet, which means that the body can no longer produce insulin. Type 1 Diabetes (T1D) can develop at any age, but is frequently observed in children and adolescents.Type 1 Diabetes (T1D) is the seventh most investigated indication within metabolic diseases by number of clinical trials, accounting for 8% of all clinical trials initiated since 1995.

Globally, Type 1 Diabetes (T1D) pipeline features 236 products across all stages of clinical development, with insulin and small molecules prominently featured in Phase III. Insulins, vaccines, and monoclonal antibodies dominate the early-stage pipeline.

Multiple big pharma developers (Novo Nordisk, Eli Lilly, and Sanofi) are investigating "smart insulin," insulin that can detect and respond to glucose levels. And for Stem Cell Therapy research, big pharma once again has a large presence, with AstraZeneca, Johnson and Johnson, Novo Nordisk, and Sanofi gearing up to develop novel treatments that target diabetes.

Overall, it is expected that new insulins and SGLT inhibitor approvals will drive Type 1 Diabetes market growth during the next decade.

The report "Type 1 Diabetes: Competitive Landscape to 2026", provides an assessment of the pipeline, clinical, and commercial landscape of Type 1 Diabetes along with an analysis of key market events and the future competitive environment.

Scope

This report combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the slide deck include -

  • Pipeline Assessment: regional breakdown, promising late-stage products, early-stage pipeline by molecule type
  • Clinical Trials Assessment: trial breakdown by phase, leading industry and non-industry sponsors, enrollment analytics
  • Commercial Assessment: leading marketed products, current and future players
  • Competitive Landscape Analysis: key market events (2016-2026).

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Type 1 Diabetes (T1D) market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Type 1 Diabetes (T1D) market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Preface 2

  • 1.1 Table of Contents 2
  • 1.2 Abbreviations 3
  • 1.3 Related Reports 4
  • 1.4 Upcoming Related Reports 5

2. Executive Summary 6

  • 2.2 Key Findings 7
  • 2.2 Key Events 8

3. Introduction 9

  • 3.1 Report Scope 10
  • 3.2 Disease Overview and Epidemiology 12

4. Pipeline Assessment 14

  • 4.1 Pipeline Overview 15
  • 4.2 Pipeline Breakdown by Region/Country 17
  • 4.3 Pipeline Breakdown by Molecule Type and Target 18
  • 4.4 Drug Review Designations 19
  • 4.5 Products in Clinical Development 20

5. Clinical Trial Assessment 22

  • 5.1 Clinical Trials Overview 23
  • 5.2 Top Sponsors of Clinical Trials in T1D 24
  • 5.3 Trial Breakdown by Region 26
  • 5.4 Therapy Area Perspective 27
  • 5.5 Enrollment Analytics 28

6 Commercial Assessment 31

  • 6.1 LeadingMarketed Products 32
  • 6.2 Current & Future Players 33

7. Competitive Landscape Analysis (2016-2026) 34

  • 7.1 Events Classification Overview 35
  • 7.2 US 36
  • 7.3 5EU 37
  • 7.4 Japan and China 38

8 Appendix 39

  • 8.1 Sources 40
  • 8.2 Methodology 41
  • 8.3 Key Events Included in the Analysis 42
  • 8.4 About the Authors 43
  • 8.5 About GlobalData 46
  • 8.6 Disclaimer 48
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.